文献速递中枢神经肿瘤放疗胸部肿瘤放疗

伏立诺他与立体定向放射外科同步治疗非小细胞肺癌脑转移的Ⅰ期剂量递增试验

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-05-06

这项多中心Ⅰ期3+3剂量递增试验纳入1–4个≤2 cm的非小细胞肺癌脑转移患者,伏立诺他200、300、400 mg口服每日一次共14天,第3天行单次立体定向放射外科。未观察到剂量限制性毒性,最大耐受剂量定为400 mg;中位随访12个月,Kaplan-Meier总生存13个月,无局部失败,400 mg组1例(8%)发生组织学证实的4级放射性坏死。

要点

  • 伏立诺他同步SRS的最大耐受剂量为400 mg口服每日一次共14天。
  • 未观察到剂量限制性毒性,但5例患者提前停用伏立诺他并退出研究。
  • 中位随访12个月时Kaplan-Meier总生存13个月,无局部失败。

核心结论

  • 伏立诺他与同步SRS的最大耐受剂量确定为400 mg。
  • 虽无剂量限制性毒性,但5例患者未完成治疗即退出,提示伏立诺他给药期间需支持治疗。
  • 研究期间无局部失败,可能需要更大规模随机试验评估耐受性与潜在局部控制获益。

研究设计与样本

  • 多中心Ⅰ期3+3剂量递增试验,纳入1–4个非小细胞肺癌脑转移、每个≤2 cm的患者。
  • 伏立诺他剂量水平为200、300、400 mg口服每日一次共14天,第3天行单次立体定向放射外科。
  • 2009至2014年入组17例患者,12例完成研究治疗。

主要发现

  • 未观察到剂量限制性毒性,最大耐受剂量为400 mg。
  • 10例患者(59%)报告急性不良事件。
  • 5例患者提前停用伏立诺他并退出研究,最常见退出原因为呼吸困难(n=2)、恶心(n=1)和疲乏(n=2)。
  • 中位随访12个月(范围1–64个月),Kaplan-Meier总生存为13个月。
  • 无局部失败;400 mg剂量组1例(8%)2.0 cm转移灶患者在SRS后2个月发生组织学证实的4级放射性坏死。

关键数值与推荐

  • 剂量限制性毒性定义为伏立诺他或SRS相关、30天内发生的任何常见不良事件评价标准3.0版3–5级急性非血液学不良事件。
  • 伏立诺他剂量水平为200、300、400 mg口服每日一次共14天,单次SRS于第3天实施。
  • 入组标准为1–4个非小细胞肺癌脑转移,每个转移灶≤2 cm。

临床怎么用

  • 伏立诺他同步SRS治疗非小细胞肺癌脑转移时,最大耐受剂量为400 mg口服每日一次共14天。
  • 治疗期间需关注呼吸困难、恶心和疲乏等不良事件,并加强支持治疗以减少提前退出。
  • 该方案在研究期间未观察到局部失败,但需更大规模随机试验进一步评估耐受性与局部控制获益。

局限性

  • Ⅰ期剂量递增试验样本量小,仅17例入组、12例完成研究治疗。
  • 5例患者提前停用伏立诺他并退出研究,可能影响耐受性与疗效评估。
  • 随访时间范围较宽(1–64个月),中位随访12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the maximum tolerated dose (MTD) of vorinostat, a histone deacetylase inhibitor, given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLC) brain metastases. Secondary objectives were to determine toxicity, local failure, distant intracranial failure, and overall survival rates. MATERIALS AND METHODS: In this multicenter study, patients with 1 to 4 NSCLC brain metastases, each ≤2 cm, were enrolled in a phase 1, 3 + 3 dose escalation trial. Vorinostat dose levels were 200, 300, and 400 mg orally once daily for 14 days. Single-fraction SRS was delivered on day 3. A dose-limiting toxicity (DLT) was defined as any Common Terminology Criteria for Adverse Events version 3.0 grade 3 to 5 acute nonhematologic adverse event related to vorinostat or SRS occurring within 30 days. RESULTS: From 2009 to 2014, 17 patients were enrolled and 12 patients completed study treatment. Because no DLTs were observed, the MTD was established as 400 mg. Acute adverse events were reported by 10 patients (59%). Five patients discontinued vorinostat early and withdrew from the study. The most common reasons for withdrawal were dyspnea (n=2), nausea (n=1), and fatigue (n=2). With a median follow-up of 12 months (range, 1-64 months), Kaplan-Meier overall survival was 13 months. There were no local failures. One patient (8%) at the 400-mg dose level with a 2.0-cm metastasis developed histologically confirmed grade 4 radiation necrosis 2 months after SRS. CONCLUSIONS: The MTD of vorinostat with concurrent SRS was established as 400 mg. Although no DLTs were observed, 5 patients withdrew before completing the treatment course, a result that emphasizes the need for supportive care during vorinostat administration. There were no local failures. A larger, randomized trial may evaluate both the tolerability and potential local control benefit of vorinostat concurrent with SRS for brain metastases.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Choi CYH, Wakelee HA, Neal JW, et al. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816142. doi:10.1016/j.ijrobp.2017.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。